Trial Profile
Predictors of disease recurrence after discontinuation of Imatinib in patients with Chronic Myeloid Leukemia (CML)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Jan 2017
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 17 Jan 2017 New trial record
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology